EquityFolio

ALNY

NASDAQ HEALTHCARE

Alnylam Pharmaceuticals Inc

$225.06

-$2.60 (-1.14%)

Live quote

52w: $197.81 – $484.61

Loading chart…
P/E Ratio97.09
P/B Ratio22.50
EV/EBITDA—
Debt/Equity—
ROE23.17%
ROIC—
Revenue Growth65.19%
Gross Margin—
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Own ALNY? Track it here.

Create a free account to add ALNY to a portfolio and watch your P/L update in real time.

Custom screens, valuation models and backtesting are coming to Pro.

Create a free account